Packaging of the human genome in the form of chromatin is critical for dictating which parts of the genome can be transcribed and which cannot. Cancer biologists have long known that defects in chromatin organization allows cancers to thrive and that destabilizing such defects can drive cancer cell death. TippingPoint Biosciences is the first company to tackle the core problem of targeting and drugging only the defectively packaged regions of the cancer genome, without affecting other correctly packaged regions by recreating specific chromatin states. TippingPoint’s genome state drugs will become the next generation therapies for hard-to-treat diseases with unmet needs.